Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gene therapy
|
| gptkbp:clinicalTrialPhase |
Phase 1/2
|
| gptkbp:developedBy |
gptkb:BridgeBio_Pharma
|
| https://www.w3.org/2000/01/rdf-schema#label |
BBP-631
|
| gptkbp:indication |
congenital adrenal hyperplasia
|
| gptkbp:mechanismOfAction |
AAV5 vector delivering CYP21A2 gene
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sponsor |
gptkb:BridgeBio_Pharma
|
| gptkbp:status |
investigational
|
| gptkbp:targetGene |
gptkb:CYP21A2
|
| gptkbp:therapeuticArea |
rare genetic diseases
|
| gptkbp:bfsParent |
gptkb:BridgeBio_Pharma
|
| gptkbp:bfsLayer |
8
|